company background image
A085660 logo

ChabiotechLtd KOSDAQ:A085660 Stock Report

Last Price

₩15.17k

Market Cap

₩850.9b

7D

-0.5%

1Y

-8.6%

Updated

21 Nov, 2024

Data

Company Financials

Chabiotech Co.,Ltd.

KOSDAQ:A085660 Stock Report

Market Cap: ₩850.9b

A085660 Stock Overview

A bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. More details

A085660 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Chabiotech Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChabiotechLtd
Historical stock prices
Current Share Price₩15,170.00
52 Week High₩21,000.00
52 Week Low₩13,510.00
Beta0.16
11 Month Change-12.82%
3 Month Change-7.78%
1 Year Change-8.61%
33 Year Change-21.19%
5 Year Change3.20%
Change since IPO103.26%

Recent News & Updates

Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Nov 12
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Recent updates

Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Nov 12
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

Mar 01
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

Jan 25
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Dec 21
The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Shareholder Returns

A085660KR HealthcareKR Market
7D-0.5%3.6%2.3%
1Y-8.6%-4.4%-3.8%

Return vs Industry: A085660 underperformed the KR Healthcare industry which returned -4.4% over the past year.

Return vs Market: A085660 underperformed the KR Market which returned -3.8% over the past year.

Price Volatility

Is A085660's price volatile compared to industry and market?
A085660 volatility
A085660 Average Weekly Movement5.0%
Healthcare Industry Average Movement10.1%
Market Average Movement5.7%
10% most volatile stocks in KR Market11.4%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A085660 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002256Hoon Oh Sangwww.chabio.com

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.

Chabiotech Co.,Ltd. Fundamentals Summary

How do ChabiotechLtd's earnings and revenue compare to its market cap?
A085660 fundamental statistics
Market cap₩850.91b
Earnings (TTM)-₩2.60b
Revenue (TTM)₩1.01t

0.8x

P/S Ratio

-328.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A085660 income statement (TTM)
Revenue₩1.01t
Cost of Revenue₩749.63b
Gross Profit₩260.17b
Other Expenses₩262.77b
Earnings-₩2.60b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-46.17
Gross Margin25.76%
Net Profit Margin-0.26%
Debt/Equity Ratio77.6%

How did A085660 perform over the long term?

See historical performance and comparison